Business Wire

MA-NETSCOUT-SYSTEMS

21.9.2021 12:03:07 CEST | Business Wire | Press release

Share
Cybercriminal Attacks Accelerate Global Cybersecurity Crisis According to 1H2021 NETSCOUT Threat Intelligence Report

NETSCOUT SYSTEMS, INC., (NASDAQ: NTCT) today announced findings from its bi-annual Threat Intelligence Report that underscore the dramatic impact cyberattacks continue to have on private and public organizations and governments worldwide. In the first half of 2021, cybercriminals launched approximately 5.4 million Distributed Denial of Services (DDoS) attacks, increasing 11% over 1H2020 figures. Additionally, data projections from NETSCOUT's Active Level Threat Analysis System (ATLAS™) Security Engineering and Response Team (ASERT) point to 2021 as another record-setting year on track to surpass 11 million global DDoS attacks. ASERT expects this long tail of attacker innovation to last, fueling a growing cybersecurity crisis that will continue to impact public and private organizations.

In the wake of Colonial Pipeline, JBS, Harris Federation, Australian broadcaster Channel Nine, CNA Financial, and several other high-profile attacks, the impact of DDoS and other cybersecurity attacks has been felt worldwide. As a result, leading governments are introducing new programs and policies to defend against attacks, and policing organizations are initiating unprecedented collaborative efforts to address the crisis.

During 1H2021, cybercriminals weaponized and exploited seven newer reflection/amplification DDoS attack vectors putting organizations at greater risk. This attack vector explosion spurred an increase in multivector DDoS attacks with a record-setting 31 attack vectors deployed in a single attack against one organization.

Other key findings from the NETSCOUT 1H2021 Threat Intelligence Report include:

  • New adaptive DDoS attack techniques evade traditional defenses. By customizing their strategies, cybercriminals evolved their attack efforts to bypass cloud-based and on-premise static DDoS defenses to target commercial banks and credit card processors.
  • Connectivity supply chain increasingly under attack. Bad actors looking to cause the most collateral damage focused their efforts on vital internet components, including DNS servers, virtual private network (VPN) concentrators, services, and internet exchanges, disrupting essential gateways.
  • Cybercriminals add DDoS to their toolkit to launch triple extortion campaigns. Ransomware has become big business, with extortionists adding DDoS to their attack regimen to ratchet up the pressure on victims and add stress to security teams. Triple extortion combines file encryption, data theft, and DDoS attacks, increasing the possibility that cyber criminals receive payment.
  • The fastest DDoS attack recorded a 16.17% year-over-year increase. A Brazilian wireline broadband internet user launched the attack, which was likely related to online gaming. Using DNS reflection/amplification, TCP ACK flood, TCP RST flood, and TCP SYN/ACK reflection/amplification vectors, the sophisticated attack recorded 675 Mpps.
  • The largest DDoS attack, 1.5 Tbps, represented a year-over-year increase of 169%. ASERT data identified this attack against a German ISP, deploying a DNS reflection/amplification vector. This attack represents a dramatic increase in size over any attacks recorded in 1H2020.
  • Botnets contribute to major DDoS activity - Tracked botnet clusters and high-density attack-source zones worldwide showcased how malicious adversaries abused these botnets to participate in more than 2.8 million DDoS attacks. In addition, well-known IoT botnets Gafgyt and Mirai continue to pose a severe threat contributing to more than half of the total number of DDoS attacks.

"Cybercriminals are making front-page news launching an unprecedented number of DDoS attacks to take advantage of the pandemic's remote work shift by undermining vital components of the connectivity supply chain," stated Richard Hummel, threat intelligence lead, NETSCOUT. "Ransomware gangs added triple-extortion DDoS tactics to their repertoire. Simultaneously, the Fancy Lazarus DDoS extortion campaign kicked into high gear threatening organizations in multiple industries with a focus on ISPs and specifically their authoritative DNS servers."

NETSCOUT's Threat Intelligence Report covers the latest trends and activities in the DDoS threat landscape. It covers data secured from NETSCOUT's Active Level Threat Analysis System (ATLAS™) coupled with NETSCOUT's ATLAS Security Engineering & Response Team (ASERT) insights.

The visibility and analysis represented in the Threat Intelligence Report and Omnis® Threat Horizon fuel the ATLAS Intelligence Feed used across NETSCOUT's Omnis security product portfolio to detect and block threat activity for enterprises and service providers worldwide.

For more information on NETSCOUT's semi-annual Threat Intelligence Report, please visit our interactive website . You can also find us on Facebook , LinkedIn, and Twitter for threat updates and the latest trends and insights.

About NETSCOUT

NETSCOUT SYSTEMS, INC. (NASDAQ: NTCT) helps assure digital business services against security, availability, and performance disruptions. Our market and technology leadership stems from combining our patented smart data technology with smart analytics. We provide real-time, pervasive visibility and insights customers need to accelerate and secure their digital transformation. Our Omnis® cybersecurity advanced threat detection and response platform offers comprehensive network visibility, threat detection, highly contextual investigation, and automated mitigation at the network edge. NETSCOUT nGenius™ service assurance solutions provide real-time, contextual analysis of service, network, and application performance. And Arbor Smart DDoS Protection by NETSCOUT products help protect against attacks that threaten availability and advanced threats that infiltrate networks to steal critical business assets. To learn more about improving service, network, and application performance in physical or virtual data centers or in the cloud, and how NETSCOUT's security and performance solutions can help you move forward with confidence, visit www.netscout.com or follow @NETSCOUT on Twitter, Facebook, or LinkedIn.

©2021 NETSCOUT SYSTEMS, INC. All rights reserved. NETSCOUT, the NETSCOUT logo, Guardians of the Connected World, Adaptive Service Intelligence, Arbor, ATLAS, Cyber Threat Horizon, InfiniStream, nGenius, nGeniusONE, and Omnis are registered trademarks or trademarks of NETSCOUT SYSTEMS, INC., and/or its subsidiaries and/or affiliates in the USA and/or other countries. Third-party trademarks mentioned are the property of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/NETSCOUTinc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye